CORT•prnewswire•
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
Summary
SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant – came on January 30, 2026 when Reuters reported that...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 2, 2026 by prnewswire